Synonyms: ASP8273
Compound class:
Synthetic organic
Comment: ASP8273 is a third generation EGFR inhibitor, targeting T790M / L858R mutants. It is a structural match to example 54 in patent WO2013108754 [1].
|
|
No information available. |
Summary of Clinical Use ![]() |
ASP8273 is being evaluated in Phase 3 clinical trial as a first-line therapy for patients with EGFR mutation +ve non-small cell lung cancer (trial code NCT02588261). In this trial ASP8273 is being compared against erlotinib or gefitinib. |
Clinical Trials | |||||
Clinical Trial ID | Title | Type | Source | Comment | References |
NCT02588261 | A Study of ASP8273 vs. Erlotinib or Gefitinib in First-line Treatment of Patients With Stage IIIB/IV Non-small Cell Lung Cancer Tumors With EGFR Activating Mutations | Phase 3 Interventional | Astellas Pharma Inc |